Brief: Decibel Therapeutics Says U.K. MHRA Approves Clinical Trial Application For DB-OTO

Decibel Therapeutics

24/01/2023 12:19

Jan 24 (Reuters) - Decibel Therapeutics Inc  DBTX.O :
    * DECIBEL THERAPEUTICS ANNOUNCES APPROVAL OF CLINICAL TRIAL
APPLICATION BY THE U.K. MEDICINES AND HEALTHCARE PRODUCTS
REGULATORY AGENCY FOR LEAD GENE THERAPY CANDIDATE DB-OTO
    * DECIBEL THERAPEUTICS INC - INTENDS TO INITIATE PHASE 1/2
CLINICAL TRIAL OF DB-OTO IN FIRST HALF OF 2023
    * DECIBEL THERAPEUTICS INC - ONE-TIME ADMINISTRATION OF
DB-OTO HAS
RESULTED IN PRODUCTION OF OTOFERLIN PROTEIN
    * DECIBEL THERAPEUTICS - ONE-TIME ADMINISTRATION OF DB-OTO
RESULTED IN DURABLE AUDITORY BRAINSTEM RESPONSES TO SOUND IN
CONGENITALLY DEAF RODENT DISEASE MODEL
    * DECIBEL - CTA AUTHORIZATION FOR DB-OTO PROVIDES APPROVAL
TO
EXPAND ITS PLANNED PHASE 1/2 CLINICAL TRIAL TO U.K. IN PATIENTS
2 YEARS OF AGE AND YOUNGER
    * DECIBEL THERAPEUTICS INC - EXPECT TO SHARE INITIAL DATA
FROM
FIRST COHORT OF PATIENTS IN Q1 OF 2024 FROM DB-OTO
    * DECIBEL THERAPEUTICS INC - INTENDS TO PROVIDE AN UPDATE ON
DESIGN OF CLINICAL TRIAL IN MID-2023 FOR DB-OTO

Source text for Eikon:  ID:nGNX2X6cmc 
Further company coverage:  DBTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))